3Baccarani M,Saglio G,Goldman J,et al.Evolving concepts in the man-agement of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European Leukemia Net[J].Blood,2006;108(6):1809-20.
7Cortes J,Giles F,O'Brien S,et al.Result of high-dose imatinib mesylate in patients with Philadephia chromosome-positive chronic mycloid leuke-mia after failure of interferon-alpha[J].Blood,2003;102(1):83-6.
8Schiffer CA,Hehlmann R,Larson R.Perspectives on the treatment of chronic phase and advanced phase CML and Philadephia chromosome positive ALL(1)[J].Leukemia,2003;17(4):691-9.
7Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia Net. Blood, 2006 , 108 (6) : 1809-1820.
8Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells:Implications for drug resistance. Blood,2004, 104(12) :3739-3745.
9Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood,2005 ; 106(3):1133-1134.
10Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to Imatinib in chronic myeloid leukemia. Clin Pharmacol Ther,2008;83(2) :258-264.
